“If You Own Too Much Tech, You’re Going To Be Slaughtered.” Cramer Urges Investors To Take Profits
“If You Own Too Much Tech, You’re Going To Be Slaughtered.” Cramer Urges Investors To Take Profits
Danielle Liverance Thu, October 22, 2026 at 7:00 AM UTC
0
Tulane Public Relations/Wikimedia Commons (Tulane Public Relations/Wikimedia Commons)Quick Read -
Cramer urges trimming Micron (MU), up 758% in a year, and rotating into JPMorgan (JPM) at just 15 times earnings.
Wells Fargo (WFC) at 12 times earnings remains a laggard buy, and Novo Nordisk's (NVO) weakness makes Eli Lilly more attractive.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.
Jim Cramer, host of Mad Money, used his Tuesday morning appearance on CNBC's "Squawk on the Street" on July 21, 2026 to fire a warning shot at investors who rode the AI trade to fresh highs and never trimmed. His message left no room for interpretation: "Because if you own too much tech, you're going to be slaughtered. And you won't even know what hit you. For the moment, it's time to go to other sectors that can make you money without the volatility."
With futures pointing higher on renewed semiconductor strength, Cramer's instinct ran against the crowd. His rotation playbook centers on two sectors: financials and healthcare. Both offer cleaner valuations and earnings momentum that has already shown up in bank results from the prior week.
The Discipline: Take Off Half When a Group Goes Red Hot
Cramer's call is rooted in position sizing, not a blanket top call on tech. "When you have a group that is red hot, you take off half. You have to be disciplined, and the reason why you have to be disciplined is because a lot of this last run, the parabolic move, is not cured by a 20% to 30% decline because the stock went up more than that."
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.
Micron Technology (NASDAQ:MU) is the clearest illustration of the risk he has in mind. Cramer suggested a few weeks before this appearance that investors sell half their position, and the performance numbers explain why. Shares were up roughly 240% year to date at the time of publication, making Micron one of the standout performers in the S&P 500. Fiscal Q3 2026 revenue came in at $41.46 billion, up 346% from the same quarter a year earlier, with non-GAAP EPS of $25.11 versus a consensus near $20.78 and non-GAAP gross margin of 84.9%, up from 39% a year earlier. The fundamentals are real. The move is parabolic, which is precisely Cramer's point. Polymarket contracts at the time of his comments priced a 0.74 probability that Micron would close lower that same day.
Where Cramer Sees Value: Banks at 12 to 15 Times Earnings
The sector rotation has visible evidence behind it. Among the top ten Dow names year to date at the time of the interview, eight were either healthcare or financials. The July 14 bank earnings round gave the thesis fresh fuel, with several large lenders posting record quarterly results.
JPMorgan Chase (NYSE:JPM) posted Q2 EPS of $7.70 versus $5.80 expected on $57.35 billion in net revenue, a 28% year-over-year increase, and authorized a fresh $50 billion buyback. Equity markets revenue surged 86% in the quarter, helping net income reach $21.2 billion, the highest quarterly profit in the bank's history. Cramer's read on CEO Jamie Dimon: "You can buy his stock for 15 times earnings. It's one of the brightest guys in the world. Jamie and his team is filled with brilliant people. 15 times. I'll take it."
Advertisement
Bank of America (NYSE:BAC) trades at 14 times earnings, delivered a fifth consecutive EPS beat at $1.21 (versus the $1.13 consensus), and posted revenue of $31.6 billion, up 15% year over year, with net income climbing 27% to $9.1 billion. Wells Fargo (NYSE:WFC) trades at 12 times earnings and had lagged the broader market year to date at the time, which is exactly the type of unloved name Cramer is willing to buy while others chase memory chips higher.
Healthcare: Lilly the GLP-1 Winner
Cramer's second lane is pharma, and he has a specific winner in mind. "I will say, you know what? Let me go and buy some Lilly into the Novo Nordisk weakness."
Eli Lilly (NYSE:LLY) had reported Q1 2026 EPS of $8.55 versus $6.79 expected and revenue of $19.80 billion, up 55.5% year over year, with 2026 guidance at the time set at $82.0 to $85.0 billion. Since this article was first published, Lilly reported an even stronger Q2 2026 on August 5, 2026: revenue rose 48% year over year to $22.97 billion, non-GAAP EPS came in at $8.38, and the company raised its full-year 2026 revenue guidance again, this time to $85.0 to $87.0 billion. Mounjaro alone generated $9.9 billion in Q2 revenue, up 91% from the prior year, while combined Mounjaro and Zepbound revenue reached $14.9 billion in the quarter, a new record for both products. Novo Nordisk, by contrast, has struggled, guiding full-year adjusted sales to a decline of 4% to 12% at constant currency and falling sharply over the past year, which is the weakness Cramer saw as a buying opportunity for Lilly.
The Takeaway
Cramer's broader argument comes down to a single discipline: recognize when a trade has run past what any ordinary pullback could undo, trim into strength, and redeploy at reasonable multiples where earnings are compounding. Banks reporting record quarterly profits at 12 to 15 times earnings, and a pharma leader raising its guidance two quarters in a row, give him the landing spots for those profits. The rotation is not a call that tech is finished. It is a call that discipline, at a certain point in a parabolic run, beats conviction.
Editor's note: This update corrects Micron's fiscal Q3 2026 non-GAAP gross margin to 84.9% and adds post-publication context from Eli Lilly's August 5, 2026 Q2 earnings report, including Q2 revenue of $22.97 billion, non-GAAP EPS of $8.38, a raised 2026 revenue guidance range of $85.0 to $87.0 billion, and Mounjaro Q2 revenue of $9.9 billion (up 91%). JPMorgan's Q2 net income of $21.2 billion, a record for the bank, is also noted alongside confirmation of its $50 billion buyback authorization.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.
Contact editorial@247wallst.com for any questions or corrections.
Source: “AOL Money”
